studied 50 patients with oligometastatic recurrent prostate cancer (49 with PSMA PET, 10 with choline PET) and found that PSMA PET could help select patients with oligometastatic recurrent prostate cancer suitable for SABR at lower PSA levels and subsequently resulted in a significantly longer response duration (34.0 months vs. 14.7 months) and ADT-free survival (32.7 months vs. 14.9 months) compared with choline PET [24]. This evidence concerns the gene KLK3 and prostate carcinoma.